1,057 results on '"Paganelli, Giovanni"'
Search Results
2. Radioligand therapies in cancer: mapping the educational landscape in Europe
3. 177Lu-PSMA therapy in metastatic prostate cancer: An updated review of prognostic and predictive biomarkers
4. Impact of liver tumour burden, alkaline phosphatase elevation, and target lesion size on treatment outcomes with 177Lu-Dotatate: an analysis of the NETTER-1 study
5. Neuroendocrine Tumors: Therapy with Radiolabeled Peptides
6. Diagnostic Applications of Nuclear Medicine: Neuroendocrine Tumors
7. Computed tomography based analyses of body mass composition in HER2 positive metastatic breast cancer patients undergoing first line treatment with pertuzumab and trastuzumab
8. Modelling a new approach for radio-ablation after resection of breast ductal carcinoma in-situ based on the BAT-90 medical device
9. Dosimetric Approaches for Radioimmunotherapy of Non-Hodgkin Lymphoma in Myeloablative Setting
10. Circulating androgen receptor gene amplification and resistance to 177Lu-PSMA-617 in metastatic castration-resistant prostate cancer: results of a Phase 2 trial
11. Avidin-biotin approach for cancer therapy and new biotin derivatives
12. Combined use of 177Lu-DOTATATE and metronomic capecitabine (Lu-X) in FDG-positive gastro-entero-pancreatic neuroendocrine tumors
13. 177Lu-PRRT in advanced gastrointestinal neuroendocrine tumors: 10-year follow-up of the IRST phase II prospective study
14. Dosimetry and safety of 177Lu PSMA-617 along with polyglutamate parotid gland protector: preliminary results in metastatic castration-resistant prostate cancer patients
15. Spotlight on PSMA as a new theranostic biomarker for bladder cancer
16. Plasma tumour DNA as an early indicator of treatment response in metastatic castration-resistant prostate cancer
17. A metastatic tumor is no different to a viral pandemic: lessons learnt from COVID-19 may teach us to change the PRRT paradigm
18. SUV95th as a Reliable Alternative to SUVmax for Determining Renal Uptake in [68Ga] PSMA PET/CT
19. PRRT neuroendocrine tumor response monitored using circulating transcript analysis: the NETest
20. Role of Functional Imaging in the Diagnosis of Neuroendocrine Tumors
21. POSTER: MM-602 Role of the Combination of FDG-PET Plus Whole Body MRI for Staging Patients With High-Risk Smoldering Myeloma: A Prospective Trial
22. MM-602 Role of the Combination of FDG-PET Plus Whole Body MRI for Staging Patients With High-Risk Smoldering Myeloma: A Prospective Trial
23. P953: ROLE OF THE COMBINATION OF FDG PET PLUS WHOLE BODY MRI FOR STAGING NEWLY DIAGNOSED AND RELAPSED/REFRACTORY MULTIPLE MYELOMA: A PROSPECTIVE TRIAL
24. P918: ROLE OF THE COMBINATION OF FDG PET PLUS WHOLE BODY MRI FOR STAGING PATIENTS IN HIGH RISK SMOLDERING MYELOMA: A PROSPECTIVE TRIAL
25. Neuroendocrine Tumors: Therapy with Radiolabeled Peptides
26. Diagnostic Applications of Nuclear Medicine: Neuroendocrine Tumors
27. Nuclear Medicine in the Clinical Management (ROLL, SNB, and PET)
28. Circulating hsa-miR-5096 predicts 18F-FDG PET/CT positivity and modulates somatostatin receptor 2 expression: a novel miR-based assay for pancreatic neuroendocrine tumors
29. Interim analysis of the REASSURE (Radium-223 alpha Emitter Agent in non-intervention Safety Study in mCRPC popUlation for long-teRm Evaluation) study: patient characteristics and safety according to prior use of chemotherapy in routine clinical practice
30. 68Ga-PSMA-PET: added value and future applications in comparison to the current use of choline-PET and mpMRI in the workup of prostate cancer
31. 68Ga-PSMA PET/CT in patients with recurrent prostate cancer after radical treatment: prospective results in 314 patients
32. Radiology imaging management in an Italian cancer center (IRST IRCCS) during the COVID-19 pandemic
33. Author Correction: A new microdispersed albumin derivative potentially useful for radio-guided surgery of occult breast cancer lesions
34. CAR-T cell therapy: a potential new strategy against prostate cancer
35. PRRT genomic signature in blood for prediction of 177Lu-octreotate efficacy
36. Investigation of receptor radionuclide therapy with 177Lu-DOTATATE in patients with GEP-NEN and a high Ki-67 proliferation index
37. Prognostic value of 18F–choline PET/CT metabolic parameters in patients with metastatic castration-resistant prostate cancer treated with abiraterone or enzalutamide
38. Yttrium-90 Labelled Anti-CD20 Radioimmunotherapy with Stem Cells Support
39. Intracavitary Use of Radionuclides and Treatment of Meningiomas
40. In Vivo Models for the Performance and Safety of BAT-90, a Novel 90-Yttrium-based Internal Radiotherapy Platform
41. Clinical Application of the Avidin-Biotin System for Tumor Targeting
42. A new microdispersed albumin derivative potentially useful for radio-guided surgery of occult breast cancer lesions
43. 177Lu-DOTATATE Efficacy and Safety in Functioning Neuroendocrine Tumors: A Joint Analysis of Phase II Prospective Clinical Trials
44. MODELLING A NEW APPROACH FOR RADIO ABLATION AFTER RESECTION OF BREAST DUCTAL CARCINOMA IN SITU BASED ON THE BAT 90 MEDICAL DEVICE
45. Reduction of 68Ga-PSMA renal uptake with mannitol infusion: preliminary results
46. Long-term follow-up and role of FDG PET in advanced pancreatic neuroendocrine patients treated with 177Lu-D OTATATE
47. Radioimmunotherapy in Brain Tumors
48. Local Accelerated Radionuclide Breast Irradiation: Avidin-Biotin Targeting System
49. Neuroendocrine Tumors
50. Dosimetry Using SPECT-CT
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.